Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model

BackgroundIrinotecan is a topoisomerase I inhibitor that is commonly used as a chemotherapeutic regimen for the treatment of metastatic colorectal cancer (CRC) by producing cytotoxic DNA damage. However, drug resistance frequently occurs, underscoring the importance of developing newer treatment str...

Полное описание

Библиографические подробности

Главные авторы:	Robert W. Lentz, Adrian T. A. Dominguez, Nicole Baranda Balmaceda, John J. Arcaroli, Stacey M. Bagby, Cameron A. Binns, Stephen G. Smoots, Marilyn M. Jackson, Morgan Macbeth, Tessa Holmstoen, Tapahsama Banerjee, Phaedra A. Whitty, S. Stephen Yi, Christopher H. Lieu, Wells A. Messersmith, Todd M. Pitts
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2026-03-01
Серии:	Frontiers in Oncology
Предметы:	chemotherapy colorectal cancer eltanexor selinexor XPO1
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1721685/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!